OptimizeRx Set to Join S&P SmallCap 600, To Replace Lydall, Effective Monday, October 4th
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210929-1443822/1443822_ldl6.pdf
OptimizeRx Announces Significant Platform Enhancement To Digitize Pharmaceutical Access Solutions
OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced the launch of its new Therapy
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 183 stocks hit new 52-week highs.
OptimizeRx Reports Partnership With Demandbase For Exclusive Account-Based Experience, No Terms Disclosed
OptimizeRx Corp. (the “Company”) (NASDAQ:OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, and Demandbase, the B2B go-to-market leader, today
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.
OptimizeRx: Q2 Earnings Insights
Shares of OptimizeRx (NASDAQ:OPRX) moved lower in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 400.00% year over year to $0.10, which beat the estimate of $0.07.
OptimizeRx Q2 EPS $0.10 Beats $0.07 Estimate, Sales $13.60M Beat $12.45M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. This is a 400 percent increase over earnings of $0.02 per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.